BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
5 Breakout Stars in Ongoing television Series - 2Cheetos and Doritos to launch new versions without artificial dyes
- 3In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- 4Fundamental Home Machines for Improved Solace in Summer
- 52026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Disability rights activist and author Alice Wong dies at 51
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- Kennedy approves adding two rare disorders to newborn screenings
- Protester climbs on to balcony of Iranian embassy in London
- Auschwitz Committee wants German auction of Holocaust items scrapped
- Solid Propensities: Little Changes for a Superior Life
- If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
